Dermata Therapeutics Inc. (DRMA)
NASDAQ: DRMA
· Real-Time Price · USD
0.77
-0.01 (-1.22%)
At close: May 14, 2025, 3:16 PM
-1.22% (1D)
| Bid | 0.74 |
| Market Cap | 4.65M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -12.29M |
| EPS (ttm) | -8.03 |
| PE Ratio (ttm) | -0.1 |
| Forward PE | -0.78 |
| Analyst | Buy |
| Ask | 0.82 |
| Volume | 69,398 |
| Avg. Volume (20D) | 1,542,658 |
| Open | 0.77 |
| Previous Close | 0.78 |
| Day's Range | 0.76 - 0.79 |
| 52-Week Range | 0.69 - 5.79 |
| Beta | 0.59 |
About DRMA
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol DRMA
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for DRMA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
+5.19%
Dermata shares are trading higher after the compan...
Unlock content with
Pro Subscription
5 months ago
+19.01%
Dermata Therapeutics shares are trading higher after the company received a notice of allowance for a U.S. patent titled "COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN CONDITIONS (INCLUDING ACNE)"
4 weeks ago · accessnewswire.com
Dermata's XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks- Dermata previously announced XYNGARI(TM) produced highly statistically significant topline data for all primary endpoints at week 12 in Phase 3 trial - - Additional data analysis revealed that XYNGA...
1 month ago · accessnewswire.com
Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results- Dermata expects to announce topline results from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial by end of March 2025 - - The Company recently entered into a Clinic...
